THE WIRE · № 65813
AbbVie and Genmab Announce Epcoritamab in Combination with R-CHOP Demonstrates Significant Improvement in Progression-Free Survival versus R-CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
01 THE MACHINE READ
WHY IT MATTERS.
A Phase 3 PFS win for a bispecific combo in frontline DLBCL supports the bispecific-antibody class and the sponsor's oncology pipeline.
Bispecific combo shows frontline lymphoma benefit
Regulatory filing and full data presentation
Mature data, safety, or approval delays
FULL DISPATCH
EPCORE DLBCL-2 is the first Phase 3 study of a bispecific antibody combination therapy to demonstrate statistically significant and clinically meaningful improvement in progression-free survival (PFS) in frontline diagnosed diffuse large B-cell lymphoma (DLBCL) patients Based on the...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
CPI | Invisalign Maker Must Face Renewed Antitrust Litigation2026-10-05 18:41 UTC
In test of investors' appetite, Lilly-connected TRex Bio plots $153 million IPO2026-10-05 19:31 UTC
TRex shoots for $125M IPO to fund Treg-boosting therapies2026-10-05 20:33 UTC
Trump is promising $90 Medicare rebate checks ahead of the midterms. Here’s the hidden cost.2026-10-05 20:39 UTC
Report of Possible $5 Billion Takeover Bid Sends Option Care Health Stock Higher2026-10-05 21:16 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.